Clinical Trials Browser

Phase 1/2 × Completed × auricularum × Clear all

NCT01864018 2025-07-24

Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis

Phase 1/2 Completed

87 enrolled 13 charts

Amyloidosis, Multiple Myeloma

NCT02633059 2024-09-19

Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 1/2 Completed

33 enrolled 26 charts

Chromosome 17 deletion, Multiple Myeloma

NCT00477412 2022-01-28

Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

Phase 1/2 Completed

107 enrolled 14 charts

Lymphoma, Mantle-Cell

NCT01381692 2021-10-04

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Phase 1/2 Completed

9 enrolled 8 charts

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00966693 2020-11-04

Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma

Phase 1/2 Completed

77 enrolled 19 charts

Multiple Myeloma